We have recently demonstrated the feasibility, tolerability, and clinical efficacy of a technological platform, termed encapsulated cell biodelivery (ECB), in delivering the neurotrophin—nerve growth factor (NGF) to the brain of individuals with Alzheimer’s disease (AD) [3–6]. The gene discussed is NGF; the disease is early-onset autosomal dominant Alzheimer disease.